{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '37', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Posttreatment', 'Notes', 'Safety', 'Survival', 'Treatment', 'Follow-', 'Follow-', 'Follow-', 'All procedures are to', 'Study Period', 'Screening', 'Cycle = 21 Days', 'EOT', 'up', 'up', 'up', 'be performed before', '30 Days', 'study intervention', 'At', '-28 to -1', '1', '2', '3', '4', '6 to 35', 'Every', 'Every', 'Visit Timing/', '5', 'DC', 'post last', 'administration unless', '12 weeks', '12 weeks', 'Cycle Number', 'dose', 'otherwise indicated.', 'Cycle Day', 'Refer to Section 8.11', '(=3 days unless', '1', '8', '15', '1', '15', '1', '1', '1', '1', 'for visit details.', 'otherwise specified)', 'Scheduling Window', '+3', '3', '3', '3', '3', '3', '3', '3', '3', '+7', ' 7', '14', '(Days)', 'WOCBP require', 'negative test prior to', 'randomization. If more', 'than 24 hours have', 'elapsed prior to first dose', 'of study intervention,', 'Serum \u00df-HCG or', 'another pregnancy test is', 'urine pregnancy test', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'required prior to starting', '(WOCBP only)', 'study intervention.', 'A serum or urine', 'pregnancy test will be', 'performed per Appendix', '2. Refer to Sections 5.1,', '5.2, 8.3.5 and 10.5.3.', 'Required at baseline if', 'HIV, hepatitis B and', 'X', 'C screen', 'mandated by local health', 'authority.', '-Performed locally', 'Hematology and', 'within 10 days before', 'clinical chemistry', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'first dose.', 'laboratory', '-After C1, collect within', 'assessment', '3 days before dosing.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '38', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Posttreatment', 'Notes', 'Safety', 'Survival', 'Treatment', 'Follow-', 'Follow-', 'Follow-', 'All procedures are to', 'Study Period', 'Screening', 'Cycle = 21 Days', 'EOT', 'up', 'up', 'up', 'be performed before', '30 Days', 'study intervention', 'At', '-28 to -1', '1', '2', '3', '4', '6 to 35', 'Every', 'Every', 'Visit Timing/', '5', 'DC', 'post last', 'administration unless', '12 weeks', '12 weeks', 'Cycle Number', 'dose', 'otherwise indicated.', 'Cycle Day', 'Refer to Section 8.11', '(=3 days unless', '1', '8', '15', '1', '15', '1', '1', '1', '1', 'for visit details.', 'otherwise specified)', 'Scheduling Window', '+3', '3', '3', '3', '3', '3', '3', '3', '3', '+7', ' 7', '14', '(Days)', '-Performed locally', 'within 7 days before first', 'dose.', 'After C1, collect within', '3 days before dosing.', 'Urinalysis/urine', '-Urinalysis is required at', 'X', 'X', 'X', 'X', 'X', 'X', 'screening and every 4', 'dipstick testing', 'cycles for participants', 'who received', 'lenvatinib/matching', 'placebo. After C1,', 'collect within 3 days', 'before dosing.', '-Screening samples', 'collected within 10 days', 'of treatment initiation.', 'PT/INR and', 'X', '-Additional testing to be', 'aPTT/PTT', 'conducted as clinically', 'indicated for participants', 'taking anticoagulant', 'therapy.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}